Combined effects of Lapatinib and Cisplatin on colony formation of head and neck squamous cell carcinoma

Christoph Schrader, Andreas Boehm, Christian Mozet, Andreas Dietz, Julia Bertolini, Anette Reiche & Gunnar Wichmann
Introduction: Lapatinib (LAP) targets tyrosine-kinases of EGFR/HER2-receptors and hence is under investigation regarding its value within multimodal therapy concepts of advanced head and neck squamous cell carcinoma (HNSCC). Methods: The potential of LAP alone and combined with cisplatin (CIS)[for full text, please go to the a.m. URL]